Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivo
- 1 March 1991
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 21 (3) , 851-854
- https://doi.org/10.1002/eji.1830210350
Abstract
We have quantitatively studied the effect of interleukin (IL) 2 on the cytotoxic T lymphocyte (CTL) response to tumor cells in vivo. Mastocytoma P815 was transfected with murine IL 2 cDNA (P815-IL 2) and injected into syngeneic mice. The anti-tumor response was analyzed and compared with the response induced by the non-transfected cells. P815 parental cells are highly tumorigenic, causing death within 20-30 days. In contrast, IL 2-transfected cells were totally rejected. Co-injection of IL 2-secreting and parental cells resulted in the inhibition of growth of both type of tumors. In addition, the response induced by IL 2-secreting cells protected the mice against a subsequent challenge with P815. Long-term memory persisted in treated mice 3 months after tumor rejection. Frequencies of CTL precursors and CTL specific for P815 increased as a result of IL 2 secretion by the target cells. Estimates of CTL frequency at days 8 and 12 after injection were 2 to 3 times higher in mice inoculated with P815-IL 2 cells, and this correlated with tumor rejection.Keywords
This publication has 18 references indexed in Scilit:
- The biology and clinical applications of interleukin 2Immunology Today, 1990
- A novel approach to the induction of specific cytolytic T cells in vivoResearch in Immunology, 1990
- Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.The Journal of Experimental Medicine, 1990
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- Interleukin 2-induced proliferation of murine natural killer cells in vivo.The Journal of Experimental Medicine, 1990
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity.The Journal of Experimental Medicine, 1988
- Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.The Journal of Experimental Medicine, 1983
- Viral specificity of H-2-restricted T killer cells directed against syngeneic tumors induced by Gross, Friend, or Rauscher leukemia virus.The Journal of Experimental Medicine, 1979